IP Library Granted Patent US 9,127,264
Granted Patent B2
US 9,127,264 · App. 12/960,093 · Granted Sep 8, 2015

Substantially animal protein-free recombinant furin and methods for producing the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,127,264
App. No.
12/960,093
Granted
Sep 8, 2015
Kind
B2
Abstract

The present invention relates to recombinant furin (rFurin) and methods for producing rFurin. More specifically, the invention relates to substantially animal protein-free rFurin and methods for producing substantially animal protein-free rFurin.

Claims (12)

1. A composition comprising substantially animal protein-free recombinant furin lacking transmembrane and cytoplasmic domains comprising a specific activity of at least or about 400 U/μg protein and host cell protein at a concentration less than about 1.0 ng protein/U furin activity, or host cell DNA at a concentration less than about 0.5 pg DNA/U furin activity, and essentially lacking contaminating proteins from serum.

2. The composition of claim 1 comprising recombinant furin at an activity of at least or about 10000 U furin/ml.

3. The composition of claim 1 comprising recombinant furin at an activity of at least or about 450 U/μg.

4. A method of making the composition of claim 1 comprising growing a host cell transformed or transfected with a polynucleotide encoding secreted recombinant furin lacking transmembrane and cytoplasmic domains in serum-free medium in a repeated fed batch process under conditions that permit secretion of the furin into the medium, binding the secreted furin on a multimodal cation exchange resin to remove host cell protein, host cell DNA, or a combination thereof; and recovering the secreted recombinant furin from the multimodal cation exchange resin.

5. The method of claim 4 comprising the step of adapting the host cell to grow in medium with increasingly lower concentrations of serum until all serum is removed from the medium.

6. The method of claim 4 comprising transferring the host cell from growth in medium comprising serum to growth in serum-free medium.

7. The method of claim 5 or 6 , wherein the host cell is a Chinese Hamster Ovary (CHO) cell.

8. A method of processing a pro-protein comprising a furin cleavage site comprising the step of contacting the pro-protein comprising the furin cleavage site with the composition of claim 1 under conditions to cleave a pro-peptide from the pro-protein to form a mature protein.

9. The method of claim 8 , wherein the mature protein is von Willebrand Factor.

10. The method of claim 8 , wherein the mature protein is Factor VIII.

11. The composition of claim 1 , wherein the host cell is a Chinese Hamster Ovary (CHO) cell.

12. The composition of claim 1 comprising recombinant furin at an activity of at least or about 500 U/μg.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036367/0652 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036375/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2014
From: PLAUMAUER, BARBARA; VON FIRCKS, SIMONE; GRILLBERGER, LEOPOLD; HASSLACHER, MEINHARD; GEYER, ROLAND; MITTERER, ARTUR; REITER, MANFRED
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 032321/0932 →